The proBNPage reduction (PBAR) trial-results of a randomized, double blind, placebo-controlled, pilot study to fine tune an NT-proBNP-based method to assess the effect of anti-aging treatments.

After each control session, safety variables were compared with baseline values in the whole sample by paired tests, to detect possible highly significant ( P < 0.001) and clinically relevant differences.

also in 132,142 other papers

In the first case (best possible result, Supplementary Table 3 ), borderline significance could be obtained between groups and for interaction term, but without any significant progression of proBNPage over time.

also in 7,017 other papers